Focused On-demand Library for Signal transducer and activator of transcription 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q14765

UPID:

STAT4_HUMAN

Alternative names:

Alternative UPACC:

Q14765; Q96NZ6

Background:

Signal transducer and activator of transcription 4 (STAT4) is a pivotal transcriptional regulator predominantly expressed in hematopoietic cells. It orchestrates cellular growth, differentiation, and immune responses. STAT4 is instrumental in T-helper 1 cell differentiation and interferon-gamma production, contributing to immune system precision. Its activation involves tyrosine phosphorylation upon IL12 or IFN-gamma stimulation, leading to nuclear translocation and gene transcription initiation.

Therapeutic significance:

STAT4's involvement in systemic lupus erythematosus and rheumatoid arthritis underscores its therapeutic potential. Given its critical role in immune response modulation and disease pathogenesis, targeting STAT4 could offer novel treatment avenues for these autoimmune conditions. Understanding STAT4's mechanisms opens doors to innovative therapeutic strategies, potentially transforming patient outcomes in autoimmune diseases.